文献速递炎症性肠病

多中心研究与系统评价:妊娠期别嘌醇暴露

Multicentre study and systematic review: Allopurinol exposure during pregnancy.
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-10

该多中心研究收集2013年1月至2022年3月期间妊娠期接受别嘌醇治疗的炎症性肠病(IBD)患者的安全性数据,并进行系统评价。42例别嘌醇暴露妊娠中,6例(14.3%)流产,1例死产,1例新生儿先天性异常;文献汇总102例暴露妊娠中10例(7.8%)先天异常,仅IBD母亲亚组(n=76)先天异常率为2.6%。结论认为别嘌醇致畸性尚无定论,接受别嘌醇/硫嘌呤联合治疗的IBD母亲所生子女似乎未增加先天异常风险。

要点

  • 42例妊娠期别嘌醇暴露(均联合硫嘌呤)中,6例(14.3%)流产,1例死产。
  • 文献汇总102例别嘌醇暴露妊娠中,10例(7.8%)婴儿有先天异常。
  • 仅IBD母亲亚组(n=76)中,2.6%婴儿有先天异常。

核心结论

  • 别嘌醇的致畸性总体仍无定论。
  • 接受别嘌醇/硫嘌呤联合治疗的IBD母亲所生子女似乎未增加先天异常风险。

研究设计与样本

  • 多中心研究收集2013年1月至2022年3月期间妊娠期接受别嘌醇治疗的IBD患者的安全性数据。
  • 同时进行关于别嘌醇致畸潜能的系统评价。

主要发现

  • 42例别嘌醇暴露妊娠(含1例双胎妊娠),所有女性均联合使用硫嘌呤,6例(14.3%)流产,1例32周死产。
  • 1例新生儿发现先天异常(产后发现的主动脉缩窄)。
  • 3例妊娠(含双胎妊娠)为中度早产,1例为极早产;5例新生儿(15.2%)为小于胎龄儿。
  • 文献检索额外识别102例别嘌醇暴露妊娠,共129例活产(含本队列36例婴儿),10例(7.8%)婴儿有先天异常。
  • 2例(1.6%)具有相似的多种异常模式;仅IBD母亲亚组(n=76)中2.6%婴儿有先天异常(低剂量别嘌醇暴露)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data about the safety of allopurinol in pregnant women are sparsely reported. AIMS: To investigate the risk of adverse pregnancy outcome and congenital abnormalities after in utero exposure to allopurinol in inflammatory bowel disease (IBD) pregnancies and in general. METHODS: We collected safety data of patients with IBD who were treated with allopurinol during pregnancy between January 2013 and March 2022. Additionally, we performed a systematic review about the teratogenic potential of allopurinol. RESULTS: We collected data from 42 allopurinol-exposed pregnancies, including one twin pregnancy; in all women, allopurinol was combined with a thiopurine. Six pregnancies (14.3%) resulted in miscarriage and one in stillbirth at 32 weeks. A congenital anomaly was observed in one newborn (coarctation of the aorta discovered postpartum). Three pregnancies, including the twin pregnancy, ended in moderate preterm delivery and one in very preterm delivery. Five neonates (15.2%) were small for gestational age. From our literature search, we identified an additional 102 allopurinol-exposed pregnancies resulting in 129 live births, including 36 infants from our cohort. Ten infants (7.8%) were born with a congenital anomaly. Two (1.6%) had a comparable pattern of multiple anomalies. The systematic review sub-analysis including only infants born to mothers with IBD (n = 76) revealed that 2.6% of infants had congenital anomalies after in utero exposure to a low dose of allopurinol. CONCLUSIONS: Overall, the teratogenicity of allopurinol remains inconclusive. Children conceived by mothers treated for IBD with allopurinol/thiopurine co-therapy do not seem to have an increased risk of congenital anomalies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Crouwel F, Simsek M, de Boer MA, et al. Multicentre study and systematic review: Allopurinol exposure during pregnancy. Aliment Pharmacol Ther. 2024. PMID: 38984819. doi:10.1111/apt.18126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。